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ARTICLE
Crystallographic and electrophilic fragment
screening of the SARS-CoV-2 main protease
Alice Douangamath 1,2,11, Daren Fearon 1,11, Paul Gehrtz3,11, Tobias Krojer 4,11, Petra Lukacik1,2,11,
C. David Owen1,2,11, Efrat Resnick3,11, Claire Strain-Damerell1,2,11, Anthony Aimon 1,2, Péter Ábrányi-Balogh 5,
José Brandão-Neto1,2, Anna Carbery1,6, Gemma Davison7, Alexandre Dias1, Thomas D. Downes 8,
Louise Dunnett1, Michael Fairhead4, James D. Firth 8, S. Paul Jones8, Aaron Keeley5, György M. Keserü5,
Hanna F. Klein8, Mathew P. Martin9, Martin E. M. Noble 9, Peter O’Brien 8, Ailsa Powell 1,
Rambabu N. Reddi 3, Rachael Skyner 1,2, Matthew Snee1, Michael J. Waring 7, Conor Wild1,
Nir London 3✉, Frank von Delft 1,2,4,10✉ & Martin A. Walsh 1,2✉
COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no antiviral
drugs or vaccines were developed against the closely related coronavirus, SARS-CoV-1 or
MERS-CoV, despite previous zoonotic outbreaks. To identify starting points for such ther-
apeutics, we performed a large-scale screen of electrophile and non-covalent fragments
through a combined mass spectrometry and X-ray approach against the SARS-CoV-2 main
protease, one of two cysteine viral proteases essential for viral replication. Our crystal-
lographic screen identified 71 hits that span the entire active site, as well as 3 hits at the dimer
interface. These structures reveal routes to rapidly develop more potent inhibitors through
merging of covalent and non-covalent fragment hits; one series of low-reactivity, tractable
covalent fragments were progressed to discover improved binders. These combined hits offer
unprecedented structural and reactivity information for on-going structure-based drug design
against SARS-CoV-2 main protease.
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novel coronavirus, SARS-CoV-2, the causative agent of
COVID-191–3, has resulted in over one million confirmed
cases and in excess of 300,000 deaths across 188 countries
as of mid-May 20204. SARS-CoV-2 is the third zoonotic cor-
onavirus outbreak after the emergence of SARS-CoV-1 in 2002
and the Middle East Respiratory Syndrome (MERS-CoV) in
20125–7. SARS-CoV-2 is a large enveloped, positive-sense, single-
stranded RNA Betacoronavirus. The viral RNA encodes two open
reading frames that, through ribosome frame-shifting, generates
two polyproteins pp1a and pp1ab8. These polyproteins produce
most of the proteins of the replicase-transcriptase complex9. The
polyproteins are processed by two viral cysteine proteases: a
papain-like protease (PLpro) which cleaves three sites, releasing
non-structural proteins nsp1-3 and a 3C-like protease, also
referred to as the main protease (Mpro), that cleaves at 11 sites to
release non-structural proteins (nsp4-16). These non-structural
proteins form the replicase complex responsible for replication
and transcription of the viral genome and have led to Mpro and
PLPro being the primary targets for antiviral drug development10.
Structural biology, which can play a key role in drug devel-
opment, was also rapidly deployed after the 2002 SARS-CoV-1
outbreak, with earlier work by the Hilgenfeld group on Mpro of
coronarviruses10 leading to crystal structures of SARS-CoV-1
Mpro and inhibitor complexes11–14. Active sites of Coronavirus
Mpro are well conserved13,15–19, and those of enteroviruses
(3Cpro) are functionally similar: this underpins ambitions to
develop broad-spectrum antivirals. The most successful have been
peptidomimetic α-ketoamide inhibitors20, with at least one potent
variant seen as a potential antiviral drug19. Other studies have
taken the popular approach of high-throughput screens (HTS)
using very large compound libraries, followed by structural stu-
dies to elucidate the binding mode21.
Despite these efforts, drugs remain elusive that directly target
SARS-CoV-2 (rather than disease symptoms) and are verified by
clinical trials. In retrospect, this is perhaps unsurprising for the
Mpro inhibitors, as both peptidomimetic and covalent inhibition
carry risks as strategies for drug development; in general, the
simpler the molecule, the lower the risk.
We therefore applied a different approach to Mpro, using
fragment screening by high-throughput structural biology22.
Fragment methods have become a staple of modern drug dis-
covery23, using small collections (100 s or 1000 s) of small
compounds (<300 Da) that bind promiscuously and thus sample
a far larger chemical space than is achieved by HTS. The chal-
lenge is that the very weak binding of fragment hits necessitates
highly sensitive biophysical detection, careful confirmation of
binding and specialised medicinal chemistry expertise to advance
hits to potency. Their promise is that potency can be achieved
with high efficiency, simplifying the progression of molecules to
biological or clinical impact.
While the screening experiment itself has long relied on the
high throughput of solution methods like NMR or SPR23, rapid
advances in technology and automation at synchrotron radiation
sources24 has made screening directly in crystal structures rou-
tinely possible at facilities like the XChem platform at Diamond
Light Source25–28. These have been further enhanced by techni-
ques such as mass spectrometry for the discovery of covalently
binding fragments29.
In the current study, we screened Mpro of SARS-CoV-2 with
over 1250 unique fragments, identifying 74 high-value fragment
hits, including 23 non-covalent and 48 covalent hits in the active
site, and 3 hits at the vital dimerization interface. Here, these data
are detailed along with potential ways forward for rapid follow-up
design of improved, more potent, compounds.
Results
Mpro crystallizes in a ligand-free form that diffracts to near-
atomic resolution. We report the apo structure of SARS-CoV-2
Mpro with data to 1.25 Å. The construct we crystallised has native
residues at both N- and C--terminals, without cloning truncations
or appendages which could otherwise interfere with fragment
binding. Electron density is present for all residues, including 26
alternate conformations, many of which were absent in previous
lower resolution crystal structures. The protein crystallised with a
single protein polypeptide in the asymmetric unit, and the catalytic
dimer is provided by a symmetry-related molecule. The structure
aligns closely with the Mpro structures from SARS-CoV-1 and
MERS (rmsd of 0.52Å and 0.97 Å respectively). The active site is
sandwiched between two β-barrel domains, I (residue 10–99) and II
(residue 100–182) (Fig. 1a). Domain III (residue 198–306), forms a
bundle of alpha helices and is proposed to regulate dimerization30.
The C-terminal residues, Cys300-Gln306, wrap against Domain II.
However, the C terminal displays a degree of flexibility and wraps
around domain III in the N3 inhibitor complex30 (PDB ID 6LU7
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Fig. 1 The crystal structure of ligand free Mpro is amenable to X-ray fragment screening. a Cartoon representation of the Mpro dimer. The nearmost
monomer is shown with secondary structure features coloured to demarcate domains I, II, and III, in orange, cyan, and violet respectively. The active site of
the rear monomer is indicated by the presence of a peptide-based inhibitor in green, generated by aligning the ligand-free structure with pdb 6Y2F
[10.2210/pdb6y2f/pdb]. A yellow sphere indicates Ser1 from the dimer partner that completes the active site. b Residues of the active site are labelled, and
subsites involved in ligand binding are shown with circles. c Active site plasticity is observed when comparing the apo structure to peptide inhibitor bound
structures (green—Apo, grey—6Y2F [10.2210/pdb6y2f/pdb], pink 6LU7 [10.2210/pdb6lu7/pdb]). Displacement distances associated with loop
movements are indicated.
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[https://doi.org/10.2210/pdb6lu7/pdb]). His41 and Cys145 com-
prise the catalytic dyad and dimerisation completes the active site
by bringing Ser1 of the second dimer protomer into proximity with
Glu166 (Fig. 1b). This aids formation of the substrate specificity
pocket and the oxyanion hole10. Subsites have previously been
identified in the active site based on interactions with peptide-based
inhibitors and are shown in Fig. 1b19,31. Comparisons with peptide-
based inhibitor complexes19,31 suggest a degree of active site plas-
ticity. In particular, the C-alphas of Met49, Pro168, Gln189
respectively show movements of 2.8 Å, 1.4 Å, and 1.2 Å in com-
parison to the α-ketoamide inhibitor bound Mpro structure19 (PDB
ID 6y2f [https://doi.org/10.2210/pdb6y2f/pdb], Fig. 1c).
The crystal form is well-suited for crystallographic fragment
screening: although the percentage of solvent (~20%) is very low
for a protein crystal, nevertheless clear channels are present that
allow access to the active site through diffusion. Moreover, the
tight packing and strong innate diffraction mean crystals are
resistant to lattice disruption and degradation of diffraction by
DMSO solvent when adding solubilised fragments to the
crystallization drop.
Combined MS and crystallographic fragment screens reveal
new binders of Mpro. Cysteine proteases are attractive targets for
covalent inhibitors, and screening covalent fragments is known to
be useful at identifying effective starting points32–36. To identify
covalent starting points, we screened our previously described
library of ~1000 mild electrophilic fragments29 against Mpro
using intact protein mass spectrometry. Standard conditions of
200 µM per electrophile for 24 h at 4 °C did not allow dis-
crimination between hits. Screening at more stringent conditions
(5 µM per electrophile; 1.5 h; 25 °C) resulted in 8.5% of the library
labelling above 30% of protein (Supplementary Data 1). These
hits revealed common motifs, and we focused on compounds that
offer promising starting points.
Compounds containing N-chloroacetyl-N´-sulfonamido-
piperazine or N-chloroacetylaniline motifs were frequent hitters.
Such compounds can be highly reactive. Therefore, we chose
series members with relatively low reactivity for follow-up
crystallization attempts. For another series of hit compounds,
containing a N-chloroacetyl piperidinyl-4-carboxamide motif
(Supplementary Data 1) which displays lower reactivity and were
not frequent hitters in previous screens, we attempted crystal-
lization despite their absence of labelling in the stringent
conditions.
While mild electrophilic fragments are ideal for probing the
binding properties around the active site cysteine, their small size
prevents extensive exploration of the substrate-binding pocket.
We performed an additional crystallographic fragment screen to
exhaustively probe the Mpro active site, and to find opportunities
for fragment merging or growing. The 68 electrophile fragment
hits were added to crystals along with a total of 1176 unique
fragments from 7 libraries (Supplementary Table 1). Non-
covalent fragments were soaked26, whereas electrophile fragments
were both soaked and co-crystallized as previously described29, to
ensure that as many of the mass-spectrometry hits as possible
were structurally observed. A total of 1742 soaking and 1139 co-
crystallization experiments resulted in 1877 mounted crystals.
While some fragments either destroyed the crystals or their
diffraction, 1638 datasets with a resolution better than 2.8 Å were
collected. The best crystals diffracted to better than 1.4 Å, but
diffraction to 1.8 Å was more typical, and no datasets worse than
2.8 Å were included in analysis (Supplementary Fig. 2). We
identified 96 fragment hits using the PanDDA method37, all of
which were deposited in the Protein Data Bank (Supplementary
Data 2), but also immediately released through the Diamond
Light Source website (https://www.diamond.ac.uk/covid-19.
html), along with all protocols and experimental details. A
timeline of experiments is shown in Fig. 2.
Non-covalent fragment hits reveal multiple targetable sub-sites
in the active site. This unusually large screen identified
23 structurally diverse fragments that bind non-covalently and
extensively sample features of the Mpro active site and its speci-
ficity pockets/subsites (Fig. 1), along with three hits exploring the
dimer interface.
Eight fragments were identified that bind in the S1 subsite and
frequently form interactions with the side chains of the key
residues His163, through a pyridine ring or similar nitrogen-
containing heterocycle, and Glu166 through a carbonyl group in
an amide or urea moiety (Fig. 3). Several also reach across into
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Fig. 2 Timeline of crystallographic fragment screen. Progress of the Mpro fragment screening experiment from the start of protein production and
purification (9 Feb 2020) to the deposition and release of the high-resolution ligand-free structure of Mpro PDB ID 6YB7[10.2210/pdb6yb7/pdb] and the
structures of the 96 fragment hits identified in the fragment screening campaign using the XChem platform at Diamond Light Source.
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the S2 subsite. Subsite S2 has previously demonstrated greater
flexibility in comparison to the other subsites, adapting to smaller
substituents in peptide-based inhibitors but with a preference for
leucine or other hydrophobic residues19. Many fragments bound
at this location, which we termed the “aromatic wheel” because of
a consistent motif of an aromatic ring forming hydrophobic
interactions with Met49 or π–π stacking with His41, with groups
variously placed in 4 axial directions. Particularly notable is the
vector into the small pocket between His164, Met165 and
Asp187, exploited by three of the fragments (Z1220452176
(x0104), Z219104216 (x0305) and Z509756472 (×1249)) with
fluoro and cyano substituents (Fig. 3).
Of the four fragments exploring subsite S3, three contain an
aromatic ring with a sulfonamide group forming hydrogen bonds
with Gln189 and pointing out of the active site towards the
solvent interface (Fig. 3). These hits have expansion vectors
suitable for exploiting the same His164/Met165/Asp187 pocket
mentioned above.
The experiment revealed one notable conformational variation,
which was exploited by one fragment only (Z369936976 (×0397);
Fig. 4): a change in the sidechains of the key catalytic residues
His41, Cys145 alters the size and shape of subsite S1′ and thus the
link to subsite S1. This allows the fragment to bind, uniquely, to
both S1 and S1′. In S1, the isoxazole nitrogen hydrogen-bonds to
His163, an interaction that features in several other hits; and in
S1′, the cyclopropyl group occupies the region sampled by the
covalent fragments. Notably, the N-methyl group offers a vector
to access the S2 and S3 subsites.
It is established that the biological unit for similar viral
proteases such as the SARS-CoV-1 protease is a dimer38, and that
mutations at the dimer interface can disrupt proteases activ-
ity39,40 even at long range41. Thus, compounds that interfere with
dimerization might serve as quasi-allosteric inhibitors of protease
activity. In this study three compounds bound at accessible sites
of the dimer interface, that conceivably could be exploited to
design compounds to disrupt the Mpro dimer.
Fragment Z1849009686 (×1086; Fig. 5a) binds in a hydrophobic
pocket formed by the sidechains of Met6, Phe8, Arg298 and
Val303. It also mediates two hydrogen bonds to the sidechain of
Gln127 and the backbone of Met6. Its binding site is <7 Å away
from Ser139, whose mutation to alanine in SARS-CoV-1 protease
reduced both dimerization and protease activity by about 50%39,42.
Z264347221 (×1187, Fig. 5b) binds similarly in a hydrophobic
pocket made by Met6, Phe8 and Arg298 in one of the protomers,
extending across the dimer interface to interact with Ser123,
Tyr118 and Leu141 of the second protomer, including hydrogen
bonds with the sidechain and backbone of Ser123. Finally,
POB0073 (x0887; York 3D library; Fig. 5c), binds only 4 Å from
Gly2 at the dimer interface and is encased between Lys137 and
Val171 of one protomer and Gly2, Arg4, Phe3, Lys5 and Leu282 of
the second, including two hydrogen bonds with the backbone of
Phe3.
Covalent fragment hits reveal several tractable series. The
screen further yielded 48 structures of fragments covalently
bound to the nucleophilic active site Cys145, and substrate subsite
S1´. The majority (44) fall into series explored in the mass-
spectrometry experiment and the remainder came from other
libraries.
S1´S2
M49
H41
D187
H41 C145
M165 H164
C145
S1S3
M49
Q189
H41
C145
H41
N142
M165
H163C145
E166
E166
Fig. 3 Bound fragments sample the active site comprehensively. The central surface representation is of the Mpro monomer with all fragment hits shown
as sticks, and active site subsites highlighted by coloured boxes. Each subsite is expanded along with a selection of hits to demonstrate common features
and interactions. S1: Z44592329 (x0434); S1′: Z369936976 (×0397) in aquamarine and PCM-0102372 (×1311) in magenta bound to active site cysteine;
S2: Z1220452176 (x0104); S3: Overlay of Z18197050 (×0161), Z1367324110 (×0195) and NCL-00023830 (×0946).
a c
S1´
H41
S1
C145
b
Fig. 4 Plasticity of S1´ is revealed by fragment Z369936976 (×0397).
Comparing the electrostatic surfaces of Z1129283193 (×0107) a The most
commonly observed conformation, with that of Z369936976 (x0397).
b How the shape of S1 and S1´ can change. c Sidechain movement of
catalytic residues Cys145 and His41 upon binding of Z369936976 (×0397,
magenta) compared to Z1129283193 (×0197, grey).
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In all structures with bound electrophiles, the N-chloroacetyl
carbonyl oxygen atom forms either two or three hydrogen bonds
with the backbone amide hydrogens of Gly143, Ser144 or Cys145
(Fig. 6a–c). All three compounds containing the N-chloroacetyl
piperidinyl-4-carboxamide motif (Fig. 6a) adopt a similar binding
mode pointing towards the S2 pocket, and one (PCM-0102389,
×1358) is able to form an additional hydrogen bond with the side
chain of Asn142.
Compounds with the N-chloroacetyl-N’-sulfonamido-piper-
azine motif (Fig. 6b) adopt a bent shape, pointing towards the
S2 pocket where appropriate space-filling substituents are
attached to the phenyl moiety (PCM-0102353 (×1336) and
PCM-0102395 (×0774)); otherwise, they point towards the
solvent. Most of the latter 8 structures feature a halophenyl
moiety which resides closely to Asn142, hinting at weak
halogen-mediated interactions43.
Eight compounds with a N-chloroacetyl-N´-carboxamido-
and N-chloroacetyl-N´-heterobenzyl-piperazine motif crystallized
in one binding mode with respect to the piperazinyl moiety
(Fig. 6c) (with one exception, PCM-0102287 (×0830)). Two
structures (PCM-0102277 (×1334), PCM-0102169 (×1385)) with
a 5-halothiophen-2-ylmethylene moiety exploit lipophilic parts of
S2, which is also recapitulated by the thiophenyl moiety in an
analogous carboxamide (PCM-0102306 (x1412)). The other five
structures point mainly to S2, offering an accessible growth vector
towards the nearby S3 pocket.
A series of compounds containing a N-chloroacetyl
piperidinyl-4-carboxamide motif showed promising binding
modes. To follow-up on these compounds, we performed rapid
second-generation compound synthesis. Derivatives of this
chemotype were accessible in milligram-scale by the reaction of
N-chloroacetyl piperidine-4-carbonyl chloride with various in-
house amines, preferably carrying a chromophore to ease
purification. These new compounds were tested by intact protein
mass-spectrometry to assess protein labelling (5 μM compound;
1.5 h incubation, RT; Supplementary Data 3). Amides derived
from non-polar amines mostly outcompeted their polar counter-
parts, hinting at a targetable lipophilic sub-region in this
direction. The two amides with the highest labelling PG-COV-
35 and PG-COV-34 (Fig. 6g, h) highlight the potential for further
synthetic derivatization by amide N-alkylation or cross-coupling,
respectively.
The screen revealed unexpected covalent warheads from the
series of 3-bromoprop-2-yn-1-yl amides of N-acylamino acids.
Colloquially termed PepLites, this library was developed to map
non-covalent interactions of amino acid sidechains in protein-
protein interaction hotspots, with the acetylene bromine
intended, as for FragLites44,45, as a detection tag by anomalous
dispersion in X-ray crystallography. However, bromoalkynes can
also act as covalent traps for activated cysteine thiols46 (Fig. 6d).
Two PepLites, containing threonine (NCL-00025058 (×0978))
and asparagine (NCL00025412 (×0981)) bound covalently to the
active site cysteine (Cys145), forming a thioenolether via C-2
addition with loss of bromine (Fig. 6e, f). The covalent linkage
was unexpected and evidently the result of significant non-
covalent interactions, specific to these two PepLites, that position
the electrophile group for nucleophilic attack. We note the side-
chains make hydrogen-bonding interactions with various back-
bone NH and O atoms of Thr26 and Thr24; in the case of
threonine, it was the minor 2R,3R diastereomer (corresponding
to D-allothreonine) that bound. The only other PepLite observed
(tyrosine, NCL-00024905 (×0967)) bound non-covalently to a
different subsite.
The highlighted structure-activity relationships are important
for further optimisation. Bromoalkynes have intrinsic thiol
reactivity that is lower than that of established acrylamide-
based covalent inhibitors46, which is in general desirable. The
geometry of the alkyne and its binding mode also suggest that it
a
cb
V171
K137
G2F3
R4K5
L282
Y118
L141
S123
F8
F8
R298
R298
V303
Q127
M6
M6
Fig. 5 Fragments at dimer interface indicate opportunities for allosteric modulation. The overview shows the surface of the Mpro dimer, the
protomers in grey and cyan. Fragments and surrounding residues are shown as sticks and hydrogen bonds in dashed black lines. a Z1849009686 (×1086).
b Z264347221 (×1187). c POB0073 (×0887).
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could be replaced by reversible covalent groups such as nitriles,
which would be guided by the same non-covalent interactions but
are better established as cysteine protease inhibitors.
Two covalent hits (2-cyanopyrimidine (Cov_HetLib 030
(×2097)) and 2-cyanoimidazole (Cov_HetLib 053 (×2119)
came from a library of small heterocyclic electrophiles47. These
are essentially covalent MiniFrags48, comprising five and six-
membered nitrogen-containing heterocycles with electron-
withdrawing character that activates small electrophilic sub-
stituents (halogens, ethylyl, vinyl and nitrile groups).
Both hits bound to Cys145 through an imine (Fig. 6i, j),
positioned by a local hydrogen bond network involving imine and
heterocyclic N atoms. One of these free amines provides an
immediate growth vector towards the catalytic pocket. The
compounds have reasonable stability in water49 and limited
reactivity against GSH (t1/2= 2.2 and 52.3 h, respectively), well
above suggested reactivity limits50. They are also inactive against
various covalent targets (HDAC8, MAO-A, MAO-B, MurA) and
benchmark proteins.
Discussion
The data presented herein provide many clear routes to devel-
oping potent inhibitors of Mpro from SARS-CoV-2. The bound
fragments comprehensively sample all subsites of the active site,
revealing diverse expansion vectors, and the electrophiles provide
extensive data, systematic as well as serendipitous, for designing
covalent compounds.
It is widely accepted that new small-molecule drugs cannot be
developed fast enough to help against COVID-19. Nevertheless,
as the pandemic threatens to remain a long-term problem and
vaccine candidates do not promise complete and lasting pro-
tection, antiviral molecules will remain an important line of
defence. Such compounds will also be needed to fight future
pandemics10. Our data will accelerate such efforts: ther-
apeutically, through the design of new molecules and to inform
ongoing efforts at repurposing existing drugs; and for research,
through the development of probe molecules51 to understand
viral biology. One example is the observation that fragment
Z1220452176 (×0104) is a close analogue of melatonin, although
in this case, it is unlikely that melatonin mediates direct antiviral
activity through inhibition of Mpro, given its low molecular
weight; nevertheless, melatonin is currently in clinical trials to
assess its immune-regulatory effects on COVID19 (Clinicaltrials.
gov identifier NCT04353128).
In line with the urgency, results were made available online
immediately for download. In addition, since exploring 3D data
requires specialised tools52,53, hits were made accessible on the
Fragalysis webtool (https://fragalysis.diamond.ac.uk) that allows
easy exploration of the hits in interactive 3D.
All released models were stringently assessed for reliability. On
the one hand, the whole data analysis process necessarily relied
heavily on automation that, since its initial testing, has been
extensively validated on over 100 experiments at the XChem
facility, indicating the processes are robust in generating high-
quality atomic models. On the other hand, the final selection of
models was by subjective evaluation of the fit of each atomic
model to electron density. All models were therefore reviewed by
multiple authors prior to release, and a subjective confidence
assigned to each (Supplementary Data 2). The evidence used was
the unbiased event density generated by the PanDDA method37,
which uses multi-dataset averaging to extract signal from electron
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Fig. 6 Covalent fragments are anchored at Cys145 and sample different
regions of the orthosteric Mpro binding pocket. a Fragments containing
N-chloroacetyl piperidinyl-4-carboxamide motif. b Fragments containing N-
chloroacetyl-N´-sulfonamido-piperazine motif. c Fragments containing N-
chloroacetyl-N´-carboxamido- and N-chloroacetyl-N´-heterobenzyl-
piperazine in two binding modes. The second order kinetic constants refer
to the intrinsic thiol reactivity of these fragment hits as previously
measured29. d Reaction schema of the unexpected covalent modification to
Cys145 by PepLites hits. e Threonine PepLite (NCL-00025058 (x0978))
bound covalently to active site cysteine. f Asparagine PepLite (NCL-
00025412 (x0981)) bound to active site cysteine. Labelling of Mpro by 2nd
generation compounds proven by intact protein LC-MS: g Labelling by PG-
COV-35; h Labelling by PG-COV-34. Covalently bound cyclic electrophiles:
i Cov_HetLib 030 (×2097) and j Cov_HetLib 053 (×2119).
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density that would historically have been considered too noisy to
be convincingly interpretable54; accordingly, even ligands with
low occupancy (<40%) could be confidently assessed (Supple-
mentary Note 1). Likewise this means that poor diffraction is a
common occurrence due to the crystal handling steps required for
soaking of fragments. However, for each dataset, the dominant
source of noise is low occupancy and not phase bias, since crystals
and thus datasets are only subtly different (Supplementary
Note 1).
We have previously demonstrated the benefits of merging
covalent and non-covalent fragments to make dramatic
improvements in potency29. Our dataset offers numerous oppor-
tunities and some conservative examples are shown in Fig. 7.
These can be expected to result in potent Mpro binders and
compound synthesis is ongoing.
Collectively, the covalent hits provide rational routes to inhi-
bitors of low reactivity and high selectivity. Rationally designed
covalent drugs are gaining traction, with many recent FDA
approvals55,56. Their design is based on very potent non-covalent
binding, that allows precise orientation of a low reactivity elec-
trophile, so that formation of the covalent bond is reliant on
binding site specificity, with minimal off-target effects57–59. For
fear of over-reactivity, covalent inhibitors are expunged from
high-throughput screening libraries and are typically considered
as PAINS compounds60–62. The challenge of tuning reactivity,
and the danger of reactivity-based artefacts, are considered to be
particularly marked for highly reactive nucleophiles such as the
catalytic cysteine of many proteases. This is evidenced by the very
high hit-rate we saw in our preliminary screen of electrophiles in
which more than 150 fragments labelled Mpro by >50%. Robust
characterization of the fragments’ reactivity29, and continuous
evaluation of general thiol reactivity in the selection of lead series
and during hit-to-lead optimization can address this challenge.
We note here that most of the electrophiles that we screened
(chloroacetamides and acrylamides) form irreversible adducts
with the target cysteine, whereas many protease inhibitors con-
tain aldehydes, nitriles and α-ketoamides, that can form reversible
covalent bonds.
The scale of this experiment, particularly the diversity of
libraries and density of results, likely sets a new benchmark for
ensuring a crystal-based fragment screen accelerates progression
of hits. Even cursory inspection of the fragment structures indi-
cates a very large “merge space”, i.e., the collection of compounds
that can be designed directly from spatial juxtapositions of frag-
ments. Such merges, which can be made to populate all four
subsites, might achieve potency synergistically, because the
observed interactions can be assumed to be in near-optimal
configurations, given how few there are per fragment. A thorough
exploration of merge space might be best achieved formulaically,
using computational workflows that additionally filter undesirable
molecular properties, assess synthetic tractability and predict
binding affinity. However, such integrated approaches are not
currently available in the public domain. We hope this dataset
will help spur their development and testing.
Another promising effort to explore the potential of this pre-
mise is the COVID Moonshot project (https://covid.postera.ai/
covid), where a selection of merges will be experimentally tested,
with data promptly made public. We trust that this resource will
enable the development of many new tools, approaches and
ultimately viable treatment candidates for COVID19.
Methods
Protein expression. The expression vector was constructed with a codon-
optimised gene fragment, synthesized by Integrated DNA Technologies, which
included in-fusion compatible ends for direct insertion into BamHI-XhoI digested
pGEX-6P-1 (Supplementary Table 2). The resulting plasmid yields native N- and
C-termini upon 3C protease treatment during the purification. Multiple transfor-
mant colonies were used to inoculate a starter culture supplemented with 100 µg/
ml Carbenicillin. The culture was then grown to log phase for ~8 h. Ten millilitres
of the starter culture was used to inoculate one litre of auto induction medium
supplemented with 10 ml of glycerol and 100 µg/ml carbenicillin. The cultures were
c d
ba
Fig. 7 Fragment merging opportunities can be directly inferred from many hits. Covalently bound fragments are in green shades, and non-covalent
fragments in yellow. a Overlay of Z509756472/×1249 and PCM-0102269/×0770. b Overlay of PCM-0102277/x1334 and PCM-0102269/×0770.
c Overlay of PCM-0102287/×0830 and Z219104216/×0305. d Overlay of PCM-0102340/×0692, PCM-0102277/×1334 and Z219104216/×0305.
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grown at 37 °C, 200 rpm for 5 h then switched to 18 °C, 200 rpm for 10 h. The cells
were harvested by centrifugation and stored at −80 °C
Protein purification. Cells were resuspended in 50 mM Tris pH 8, 300 mM NaCl,
10 mM Imidazole, 0.03 μg/ml Benzonase. The cells were disrupted on a high-
pressure homogeniser (3 passes, 30 kpsi, 4 °C). The lysate was clarified by cen-
trifugation at 50,000 × g. The supernatant was then applied to a Nickel-NTA
gravity column and washed and eluted with 50 mM Tris pH 8, 300 mM NaCl, and
25–500 mM imidazole pH 8. N-terminal His-tagged HRV 3 C Protease was then
added to the eluted protein at 1:10 w/w ratio. The mixture was then dialysed
overnight at 4 °C against 50 mM Tris pH 8, 300 mM NaCl, 1 mM TCEP. The
following day, the HRV 3 C protease and other impurities were removed from the
cleaved target protein by reverse Nickel-NTA. The relevant fractions were con-
centrated and applied to an S200 16/60 gel filtration column equilibrated in 20 mM
Hepes pH 7.5, 50 mM NaCl buffer. The protein was concentrated to 30 mg/ml
using a 10 kDa MWCO centrifugal filter device.
Crystallisation and structure determination. Protein was thawed and diluted to
5 mg/ml using 20 mM Hepes pH 7.5, 50 mM NaCl. The sample was centrifuged at
100,000 × g for 15 min. Initial hits were found in well F2 of the Proplex crystal-
lisation screen, 0.2 M LiCl, 0.1 M Tris pH 8, 20% PEG 8 K. These crystals were used
to prepare a seed stock by crushing the proteins with a pipette tip, suspending in
reservoir solution and vortexing for 60 s in the reservoir solution with ~10 glass
beads (1.0 mm diameter, BioSpec products). Adding DMSO to the protein solution
to a concentration of 5% and performing microseed matrix screening, many new
crystallisation hits were discovered in commercial crystallisation screens. Following
optimisation, the final crystallisation condition was 11% PEG 4 K, 6% DMSO, 0.1
M MES pH 6.7 with a seed stock dilution of 1/640. The seeds were prepared from
crystals grown in the final crystallisation condition. The drop ratios were 0.15 µl
protein, 0.3 µl reservoir solution, 0.05 µl seed stock. Crystals were grown using the
sitting drop vapour diffusion method at 20 °C and appeared within 24 h.
Initial diffraction data were collected on beamline I04 at Diamond Light Source
on a crystal grown in 0.1 M MES pH 6.5, 5% PEG6K, cryoprotected using 30%
PEG400. Data were processed using Dials63 via Xia264. The dataset was phased
with the SARS-CoV-2 Mpro in complex with the N3 inhibitor crystal structure
(PDB:6LU7 [https://doi.org/10.2210/pdb6lu7/pdb]) using Molrep in CCP4i2.
Further datasets were collected on I04-1 at Diamond Light Source on crystals
grown using the 0.1 M MES pH 6.5, 15% PEG4K, 5% DMSO condition. To create a
high-resolution dataset, datasets from 7 crystals were scaled and merged using
Aimless65. Crystal structures were manually rebuilt in Coot66 and refined using
Refmac67 and Buster68. This structure is deposited in the PDB under ID 6YB7
[https://doi.org/10.2210/pdb6yb7/pdb].
Electrophile fragment LC/MS screen. 2 µM Mpro was incubated in 50 mM Tris
pH 8 300 mM NaCl for 1.5 h at 25 °C. For initial electrophile fragment library
screen, 30 µl protein with pools of 4–5 electrophile fragments, 7.5 nL each from 20
mM DMSO stocks and for other runs 50 µl protein with 0.5 µl compounds from
0.5 mM DMSO stocks. The reaction was quenched by adding formic acid to 0.4%
final concentration. The LC/MS runs were performed on a Waters ACUITY UPLC
class H instrument, in positive ion mode using electrospray ionization. UPLC
separation used a C4 column (300 Å, 1.7 μm, 21 mm × 100 mm). The column was
held at 40 °C and the autosampler at 10 °C. Mobile solution A was 0.1% formic acid
in water, and mobile phase B was 0.1% formic acid in acetonitrile. The run flow was
0.4 mL/min with gradient 20% B for 4 min, increasing linearly to 60% B for 2 min,
holding at 60% B for 0.5 min, changing to 0% B in 0.5 min, and holding at 0% for 1
min. The mass data were collected on a Waters SQD2 detector with an m/z range
of 2− 3071.98 at a range of 1000–2000m/z. Raw data were processed using
openLYNX and deconvoluted using MaxEnt. For each well, deconvoluted peaks
were searched to match either the unlabelled protein, or labelled protein with one
or two of the compounds in the well. Labelling percentage for a compound was
determined as the % of a specific compound adduct, divided by the overall detected
protein species. Peaks whose mass could not be assigned were discarded from the
overall labelling calculation. Wells are regarded as “bad wells” if their spectra
appeared to be of a degraded protein (low intensity and deformed peak shape) or if
after deconvolution there were no clear peaks (high noise levels). No labelling was
assigned for bad wells.
Fragment screening. Fragments were soaked into crystals by adding dissolved
compound directly to the crystallisation drops. The following libraries were
screened: the DSipoised library (Enamine), a version of the poised library25; a
version of the MiniFrags library48 assembled in-house; the FragLites library45; a
library of shape-diverse 3D fragments (“York3D”)69; heterocyclic electrophiles47;
and the SpotFinder library. All fragments were in 100% DMSO at varying stock
concentrations, detailed at https://www.diamond.ac.uk/Instruments/Mx/Fragment-
Screening/Fragment-Libraries.html). In brief, 55 nl of fragment stock solutions in
DMSO (DSI-poised, FragLite, PepLites, York 3D, Covalent Heterocylces and
SpotFinder all at 500 mM, MiniFrags at 1 M and Cysteine covalent library at 20
mM) were transferred directly to 500 nl crystallisation drops using an ECHO liquid
handler giving a final compound concentration of 2–100 mM and DMSO
concentration of 10%. Drops were incubated at room temperature for ~1 h prior to
mounting and flash cooling in liquid nitrogen without the addition of further
cryoprotectant.
Electrophile fragments identified by mass spectrometry were soaked by the
same procedure as the other libraries, but in addition, they were also co-crystallised
in the same crystallisation condition as for the apo structure. The protein was
incubated with 10–20-fold excess compound (molar ratio) for ~1 h prior to the
addition of the seeds and reservoir solution (following Resnick et al.29).
Data were collected at the beamline I04-1 at 100 K and processed with the fully
automated pipelines at Diamond63,70,71, which variously combine XDS72, xia264,
autoPROC73 and DIALS63, and select resolution limits algorithmically; no manual
curation of processing parameters was applied. Further analysis was performed
through XChemExplorer27: for each dataset, the version of processed data was
selected by the default XChemExplorer score, and electron density maps were
generated with Dimple74. Ligand-binding events were identified using PanDDA37
(both the released version 0.2 and a pre-release development version (https://
github.com/ConorFWild/pandda)), and ligands were modelled into PanDDA-
calculated event maps using Coot66. Restraints were calculated with ACEDRG or
GRADE75,76, structures were refined with Refmac67 and Buster68, and models and
quality annotations cross-reviewed. Further elaboration of the PanDDA analysis is
provided in the Supplementary Note 1.
Coordinates, structure factors and PanDDA event maps for all data sets are
deposited in the Protein Data Bank under group deposition ID G_1002135,
G_1002151, G_1002152, G_1002153, G_1002156 and G_1002157. Data collection
and refinement statistics are summarised in Supplementary Data 4. The ground-
state structure and all corresponding datasets are deposited under PDB ID 5R8T
[https://doi.org/10.2210/pdb5r8t/pdb].
Synthesis of N-chloroacetyl-piperidine-4-carboxamides. N-chloroacetyl
piperidine-4-carbonyl chloride was prepared as a stock solution in dry DCM under
an atmosphere of N2. In brief, deprotecting N-Boc isonepecotic acid in 50% TFA in
DCM (v/v) at RT for 2 h yielded the corresponding TFA salt after evaporation of all
volatiles. The crude TFA salt was then re-dissolved in DCM, treated with Et3N (2
equiv.), followed by the addition of chloroacetic anhydride (1 equiv.). The reaction
mixture was stirred overnight at RT, washed with water, the organic phase dried
over MgSO4, filtered, and all volatiles removed by rotary evaporation. The crude N-
chloroacetyl piperidine-4-carboxylic acid was refluxed in excess neat SOCl2 (gas
evolution and a colour change to red occurs) for 1 h, followed by removal of excess
SOCl2 in vacuum into a liquid nitrogen-cooled trap. The remaining residue was
dried by rotary evaporation, placed under an atmosphere of nitrogen and dissolved
in dry DCM to give a stock solution of ~0.489 M (based on theoretical yield over
three steps), which was immediately used.
The corresponding amides were prepared by the addition of the acid chloride (1
equiv.) as a DCM solution to the pertinent amines (1 equiv.) in presence of
pyridine (1 equiv.) in DCM. Heterogeneous reaction mixtures were treated with a
minimal amount of dry DMF to achieve full solubility. After stirring the reaction
mixtures overnight, the solvents were removed in by rotary evaporation, re-
dissolved in 50% aq. MeCN (and a minimal amount of DMSO to achieve higher
solubility), followed by purification by (semi-)preparative RP-HPLC in mass-
directed automatic mode or manually.
Synthesis of PepLites. HATU (1.5 equiv.), DIPEA (3.0 equiv.) and the acid
starting material (1.5 equiv.) were dissolved in DMF (3–6 mL) and stirred together
at room temperature for 10 min. 3-Bromoprop-2-yn-1-amine hydrochloride was
added and the reaction mixture was stirred at 40 °C overnight. The reaction
mixture was allowed to cool to room temperature, diluted with EtOAc or DCM and
washed with saturated aqueous sodium bicarbonate solution, brine and water. The
organic layer was dried over MgSO4, filtered and evaporated to afford crude
product. The crude product was then purified by either normal or reverse-phase
chromatography.
tert-Butyl (3-bromoprop-2-yn-1-yl)carbamate. A solution of KOH (2.7 g, 48
mmol) in water (15 mL) was added dropwise to a solution of N-bocpropargylamine
(3.0 g, 19 mmol) in MeOH (45mL) at 0 °C under nitrogen. The resulting solution
was stirred at 0 °C for 10 min then bromine (1.1 mL, 21 mmol) was added drop-
wise. The reaction mixture was allowed to warm to room temperature and was
stirred at room temperature for 24 h. The reaction mixture was diluted with water
and extracted with diethyl ether. The organic extracts were combined, dried over
MgSO4 and evaporated to afford crude product. The crude product was purified by
flash silica chromatography, elution gradient 0–10% EtOAc in petroleum ether.
Pure fractions were evaporated to dryness to afford tert-Butyl (3-bromoprop-2-yn-
1-yl)carbamate (3.5 g, 79%) as a white solid. Rf= 0.34 (10% EtOAC in petroleum
ether); m.p. 108–110 °C; IR νmax (cm−1) 3345, 2982, 2219, 2121, 2082; 1H NMR
(500MHz, DMSO-d6) δ 1.39 (s), 3.76 (d, J= 5.9 Hz), 7.30 (d, J= 6.1 Hz); 13C
NMR (126MHz, DMSO-d6) δ 28.63, 30.89, 43.44, 78.46, 78.81, 155.69; LCMS m/z
ES+ [M-Boc+H]+ 133.9; HRMS calcd for C8H1279BrNO2 255.9949 [M(Br)+Na]+
found 256.0209.
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3-Bromoprop-2-yn-1-amine hydrochloride. tert-Butyl (3-bromoprop-2-yn-1-yl)
carbamate (1.1 g, 4.7 mmol) was dissolved in 4M HCl in dioxane (30 mL). The
reaction mixture was stirred at room temperature for 2 h then evaporated to
dryness to afford 3-bromoprop-2-yn-1-amine hydrochloride (0.79 g, 99%) as a
yellow solid. m.p. 169 °C; IR νmax (cm−1) 2856, 2629, 2226, 2121, 2074; 1H NMR
(500MHz, DMSO-d6) δ 3.78 (s, 2H), 8.48 (s, 3H); 13C NMR (126MHz, DMSO-d6)
δ 29.69, 49.38, 73.90; LCMS m/z ES+ [M+H]+ 134.0; HRMS calcd for C3H579BrN
1339605 [M(Br)+H]+ found 133.9598.
(2S,3R)-2-Acetamido-N-(3-bromoprop-2-yn-1-yl)-3-(tert-butoxy)butana-
mide. (2S, 3S)-2-Acetamido-N-(3-bromoprop-2-yn-1-yl)-3-(tert-butoxy)butana-
mide was synthesized according to General procedure A using (2S,3R)-2-
acetamido-3-(tert-butoxu)butanoic acid (0.41 g, 1.9 mmol). The crude product was
purified by flash silica chromatography, elution gradient 0–10% MeOH in DCM.
Pure fractions were evaporated to dryness to afford (2S, 3S)-2-acetamido-N-(3-
bromoprop-2-yn-1-yl)-3-(tert-butoxy)butanamide (0.20 g, 42%) as a white solid.
Rf= 0.46 (10% MeOH in DCM); mp: 180–183 °C; IR νmax (cm−1) 3271, 3078,
2969, 2935, 2222, 2113; 1H NMR (500 MHz, Methanol-d4) δ 1.16 (d, J= 6.2, 5.0
Hz), 1.21 (s, J= 3.9 Hz, 9H), 2.01 (s, 3H), 3.91–4.09 (m, 3H), 4.32 (d, J= 7.5 Hz,
1H); 13C NMR (126MHz, Methanol-d4) δ 18.61, 21.15, 27.27, 28.90, 41.92, 58.81,
67.21, 74.16, 75.57, 171.19, 171.92; LCMS m/z ES+ [M+H]+ 333.2; HRMS calcd
for C13H2179BrN2O3 333.2260 [M(Br)+H]+ found 333.0808.
(2S,3R)-2-Acetamido-N-(3-bromoprop-2-yn-1-yl)-3-hydroxybutanamide
(threonine PepLite). (2S,3S)-2-Acetamido-N-(3-bromoprop-2-yn-1-yl)-3-(tert-
butoxy)butanamide (80 mg, 0.24 mmol) was dissolved in anhydrous DCM (20 mL)
and TFA (10 mL) and 0 °C under nitrogen. The reaction mixture was allowed to
warm to room temperature and was stirred at room temperature for 3 h then
evaporated to dryness to afford crude product. The crude product was purified by
flash silica chromatography, elution gradient 0–15% MeOH in DCM. Pure frac-
tions were evaporated to dryness to afford (2S,3S)-2-acetamido-N-(3-bromoprop-
2-yn-1-yl)-3-hydroxybutanamide (38 mg, 57%, 93% de) as a white solid. Rf= 0.34
(10% MeOH in DCM); mp: 189–192 °C; IR νmax (cm−1) 3280, 3085, 2973, 2924,
2225, 2115; 1H NMR (500MHz, Methanol-d4) δ 1.21 (d, J= 6.4 Hz, 3H), 2.03 (s,
3H), 3.97 – 4.06 (m, 3H), 4.33 (d, J= 6.5 Hz, 1H); 13C NMR (126MHz, Methanol-
d4) δ 18.21, 21.13, 29.00, 41.79, 58.69, 67.11, 75.41, 170.88, 172.00; LCMS m/z ES+
[M+H]+ 277.1; HRMS calcd for C9H1379BrN2O3 277.1180 [M(Br)+H]+ found
277.0182.
(S)-2-Acetamido-N1-(3-bromoprop-2-yn-1-yl)succinimide (asparagine
PepLite). (S)-2-Acetamido-N1-(3-bromoprop-2-yn-1-yl)succinamide was synthe-
sized according to General procedure A using (s)-2-acetamido-5-amino-5-oxobu-
tanoic acid (155 mg, 0.89 mmol) and evaporating the reaction mixture to afford the
crude product without aqueous work-up. The crude product was purified by flash
silica chromatography, elution gradients 0–10% MeOH in DCM. Pure fractions
were evaporated to dryness to afford (S)-2-acetamido-N1-(3-bromoprop-2-yn-1-yl)
succinamide (50 mg, 30%) as a white solid. Rf= 0.18 (10% MeOH in DCM); mp:
173 °C (decomp); IR νmax (cm−1) 3421, 3277, 3208, 3072, 2922, 2226, 2116; 1H
NMR (500MHz, Methanol-d4) δ 1.99 (s, 3H), 2.58–2.75 (m, 2H), 3.98 (d, J= 1.4
Hz, 2H), 4.71 (dd, J= 7.6, 5.7 Hz, 1H); 13 C NMR (126MHz, Methanol-d4) δ
22.57, 30.61, 37.83, 43.13, 51.54, 76.84, 173.04, 173.28, 174.81; LCMS m/z ES+ [M
+H]+ 290.2; HRMS calcd for C9H1279BrN3O3 290.1170 [M(Br)+H]+ found
290.2265.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The coordinates and structure factors have been deposited in the Protein Data Bank. The
accession codes are listed in Supplementary Data 2. Other data are available from the
corresponding authors upon reasonable request.
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